Navigation Links
Schering-Plough CEO to Buy $2 Million in Common Shares
Date:1/18/2008

and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... -- Klafter & Olsen LLP has filed a,class action l..." or the,"Company") (Nasdaq: ARTC ) and certain o...Western District of Texas on behalf of all persons...Care from January 24, 2008,through July 18, 2008 (...,persons or entities who purchased call options or...
(Date:7/25/2008)...etroviral therapy may be due to genetic factors ,...new study challenges the long-held belief that the...,s ability to restore itself after HIV patients ar...y (HAART). , From 50 percent to 90 percent of H... Intravenous drug use is the main cause of both ty...
(Date:7/25/2008)...BeaconEquity.com announces the,availability of Tra... can view all of the daily trading notes for free ... Trade Alerts include: DUSA Pharmaceuticals Inc. (...(Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Ado...q: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Joi...
(Date:7/25/2008)...ificant Improvements in Members, Health, ATLANTA,... in health,care quality management solutions for h...entered into a long-term agreement with Wellmark, ...on on Quality(SM) Incent and,Reward Best Practices...primary care clinicians to promote improved qualit...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...er Medical Centre say that the antipsychotic drug,...//Clopazine is the most effective anti-psychotic d...ny people. But there are long-term health implicat...ts who need the most effective medication are betw...
...s that simply reducing the fat. It can actually pr...cGill University// . The researchers studied 1,0...The study followed these people from 1986 to 2002....rgery during this period. The results were compare...
...eaves you with a hit in the head with the ball. Wh... little dizzy and queasy// you often just continue...and nausea are two signs of concussion—one of the ...ed Shannon, head athletic trainer and instructor a...
... all the popular opinion by saying that beer is a ...bringing cheers// to all the beer lovers. Charles... at the University of California at Davis and an A...food scientists assembled here Tuesday that beer c...
Other Medicine News:Health News:Beer is More Healthier Than Wine 2
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
Blunt Tapered Tip in stainless steel.
...ipurpose gamma camera is designed for SPECT and PE...mbines the high-energy and PET imaging capability ...ECT and planar imaging, all in one unit.,The ...nd general nuclear medicine applications well beyo...
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
AXIOM Artis FA is a universal floor-mounted angiographic C-arm system whose flexible system architecture is ideal for vascular and non-vascular diagnostics and interventions. It provides complete erg
Medicine Products: